Coffee may cut liver disease risk, related mortality

Liver disease, encompassing conditions from fatty liver to cirrhosis and liver cancer, accounts for substantial morbidity and mortality globally. Identifying accessible, low-cost interventions to reduce this burden is a priority. Coffee, a widely consumed beverage, has long been an area of interest for its potential hepatoprotective properties, but the evidence base, particularly from large-scale prospective studies integrating diverse biomarkers, has been limited.^1,2

A recent analysis, published in Clin Gastroenterol Hepatol, leveraged data from the UK Biobank, a prospective cohort study of over 500,000 participants, to investigate the association between coffee consumption and liver outcomes.¹ The study included 494,585 participants, with a median follow-up of 10.7 years. Researchers collected detailed information on coffee intake, including type (ground, instant, decaffeinated) and frequency, alongside comprehensive health data, imaging biomarkers (liver fat, stiffness), and proteomic profiles.¹

What the trial actually measured

The primary endpoint was the incidence of chronic liver disease (CLD), defined by hospital admission or death due to CLD, cirrhosis, or hepatocellular carcinoma. Secondary endpoints included liver-related mortality and the impact of coffee type and additives. The study also explored the mechanistic pathways through proteomic analysis, examining how coffee consumption might alter protein expression related to liver health.^1,2

Participants completed a baseline questionnaire on their coffee habits. Researchers then linked this data to hospital admission records, death registries, and a subset of participants who underwent liver imaging (MRI-derived proton density fat fraction for liver fat and magnetic resonance elastography for liver stiffness). A further subset had plasma proteomic profiling to identify potential biomarkers influenced by coffee intake.¹

The numbers

Regular coffee consumption correlated with a significantly reduced risk of chronic liver disease. Participants who reported drinking any amount of coffee had a 21% lower risk of developing CLD (HR 0.79; 95% CI, 0.75-0.84; P<.001) compared to non-coffee drinkers. This protective effect extended to liver-related mortality, which was reduced by 49% (HR 0.51; 95% CI, 0.45-0.58; P<.001) in coffee drinkers.¹

The benefits were not limited to a specific type of coffee. Ground, instant, and decaffeinated coffee all showed similar associations with reduced CLD risk. For instance, ground coffee drinkers had a 20% lower CLD risk (HR 0.80; 95% CI, 0.74-0.86; P<.001), while instant coffee drinkers saw a 22% reduction (HR 0.78; 95% CI, 0.73-0.83; P<.001). Decaffeinated coffee also reduced CLD risk by 16% (HR 0.84; 95% CI, 0.77-0.92; P<.001). This suggests that compounds beyond caffeine contribute to the hepatoprotective effects.¹

The optimal intake appeared to be around 3-4 cups per day, where the risk reduction was most pronounced. But even lower consumption levels offered some benefit. The study also found that coffee consumption was associated with lower liver fat content and reduced liver stiffness on imaging, providing objective evidence of improved liver health. Proteomic analysis revealed alterations in several protein pathways related to inflammation, fibrosis, and metabolic regulation, supporting a mechanistic link between coffee and liver protection.^1,2

The open-label design is the obvious caveat, as participants self-reported coffee intake, which introduces potential recall bias. But the large sample size and prospective nature of the UK Biobank data mitigate some of these concerns. Confounding factors, such as diet, alcohol consumption, and physical activity, were adjusted for, but residual confounding cannot be entirely ruled out. Still, the consistency of the findings across different coffee types and the integration of imaging and proteomic biomarkers strengthen the evidence.¹

The study was not powered to detect differences in specific liver disease etiologies, such as viral hepatitis or autoimmune liver disease, and primarily focused on the general population. Whether the benefits extend equally to patients with established liver conditions or specific genetic predispositions remains an area for further investigation. For clinicians managing patients with liver disease, having a comprehensive reference like Sherlock's Diseases of the Liver and Biliary System can be invaluable for understanding the broader context of hepatobiliary health.¹

The exact mechanisms by which coffee exerts its protective effects are still under investigation. Vargas-Pozada and colleagues explored several mechanistic approaches, highlighting coffee's antioxidant, anti-inflammatory, and anti-fibrotic properties. These include modulation of hepatic stellate cell activation, reduction of oxidative stress, and improvement of insulin sensitivity. The diverse array of bioactive compounds in coffee, including chlorogenic acids, cafestol, kahweol, and caffeine, likely contribute synergistically to these effects.²

The study did not specifically address the impact of additives like sugar or milk on the hepatoprotective effects of coffee. While the primary analysis adjusted for some dietary factors, the specific interaction of coffee with various additives warrants further research. This is particularly relevant given the increasing prevalence of sweetened coffee beverages.¹